Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.46 |
| ▸ | PARP1 | P09874 | 6/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780197 | 0.94 | KDR (0.45) | KDRPARP1CHEK1KCNH2PARP2 | |
| SCHEMBL3064920 | 0.89 | PARP1 (0.48) | KDRPARP1CHEK1 | |
| SCHEMBL2782521 | 0.89 | KDR (0.44) | KDRPARP1CHEK1KCNH2PARP2 | |
| SCHEMBL2800496 | 0.85 | NPC1 (0.52) | KDRPARP1CHEK1 | |
| SCHEMBL3062940 | 0.84 | CHEK1 (0.43) | KDRPARP1CHEK1 | |
| SCHEMBL2779709 | 0.83 | CHEK1 (0.53) | KDRPARP1CHEK1 | |
| SCHEMBL2781187 | 0.83 | KDR (0.41) | KDRPARP1CHEK1KCNH2 | |
| SCHEMBL3054985 | 0.81 | PARP1 (0.40) | PARP1 | |
| SCHEMBL7904331 | 0.79 | ACHE (0.39) | KDRPARP1CHEK1KCNH2 | |
| SCHEMBL3059195 | 0.77 | PARP1 (0.45) | PARP1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | claimed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010077663-A2 | SUBSTITUTED TETRACYCLIC 1H-INDENO (1,2-B) PYRIDINE-2 (5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | TNNI3, TNNT2, ALDH1A2 | KDR 97/4885PARP1 245/4885CHEK1 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.